{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T05:25:33Z","timestamp":1755926733258,"version":"3.37.3"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"Supplement_C","license":[{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Despite available effective guideline-based preventive therapies, patients with vascular diseases remain at high-risk of recurrent ischaemic events. Novel therapeutic strategies are therefore needed in order to further reduce the residual risk that is present in these high-risk patients. The Cardiovascular Outcomes for People using Anticoagulation Strategies trial demonstrated that, in patients with chronic coronary artery disease (CAD) and peripheral artery disease (PAD), a combination of rivaroxaban 2.5 mg\/bid (vascular dose) and acetylsalicylic acid (ASA) 100 mg once daily, the so-called dual pathway inhibition (DPI), reduced cardiovascular death, stroke, or myocardial infarction by 24% and mortality by 18%, as compared with ASA-alone. The rationale that can explain the improvement of cardiovascular outcome is that platelet aggregation and fibrin formation are involved in arterial thrombosis and rivaroxaban is able to target both ways and has a synergic effect with ASA. The aim of this review is to discuss the potential mechanisms and added benefits of DPI, in patients with PAD and CAD.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suad034","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T17:38:19Z","timestamp":1682530699000},"page":"C20-C26","source":"Crossref","is-referenced-by-count":3,"title":["Low-dose rivaroxaban: can cardiovascular events be reduced?"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8552-1272","authenticated-orcid":false,"given":"Leonardo","family":"De Luca","sequence":"first","affiliation":[{"name":"Department of Cardio-Thoracic and Vascular Medicine and Surgery, Division of Cardiology, A.O. San Camillo-Forlanini , Circonvallazione Gianicolense, 87, 0052 Rome , Italy"},{"name":"UniCamillus-Saint Camillus International University of Health Sciences , Via di Sant'Alessandro, 8, 00131 Rome , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"key":"2023042617372754800_suad034-B1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"2023042617372754800_suad034-B2","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/jama.2010.1322","article-title":"Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis","volume":"304","author":"Bhatt","year":"2010","journal-title":"JAMA"},{"key":"2023042617372754800_suad034-B3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"2023042617372754800_suad034-B4","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"2023042617372754800_suad034-B5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jacc.2021.04.083","article-title":"Mortality benefit of rivaroxaban plus aspirin in patients with chronic coronary or peripheral artery disease","volume":"78","author":"Eikelboom","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2023042617372754800_suad034-B6","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.jacc.2019.07.065","article-title":"Major bleeding in patients with coronary or peripheral artery disease treated with rivaroxaban plus aspirin","volume":"74","author":"Eikelboom","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2023042617372754800_suad034-B7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1161\/CIRCULATIONAHA.120.046048","article-title":"The COMPASS trial: net clinical benefit of low-dose rivaroxaban plus aspirin as compared with aspirin in patients with chronic vascular disease","volume":"142","author":"Steffel","year":"2020","journal-title":"Circulation"},{"key":"2023042617372754800_suad034-B8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(17)32458-3","article-title":"Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Connolly","year":"2018","journal-title":"Lancet"},{"key":"2023042617372754800_suad034-B9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"key":"2023042617372754800_suad034-B10","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1161\/CIRCULATIONAHA.119.044598","article-title":"Rivaroxaban plus aspirin versus aspirin alone in patients with prior percutaneous coronary intervention (COMPASS-PCI)","volume":"141","author":"Bainey","year":"2020","journal-title":"Circulation"},{"key":"2023042617372754800_suad034-B11","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.jacc.2019.02.048","article-title":"Rivaroxaban plus aspirin in patients with vascular disease and renal dysfunction: from the COMPASS trial","volume":"73","author":"Fox","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2023042617372754800_suad034-B12","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1161\/CIRCULATIONAHA.120.046448","article-title":"Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease: insights from the COMPASS trial","volume":"141","author":"Bhatt","year":"2020","journal-title":"Circulation"},{"key":"2023042617372754800_suad034-B13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1161\/CIRCULATIONAHA.119.039609","article-title":"Rivaroxaban with or without aspirin in patients with heart failure and chronic coronary or peripheral artery disease","volume":"140","author":"Branch","year":"2019","journal-title":"Circulation"},{"key":"2023042617372754800_suad034-B14","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/ehjcvp\/pvab050","article-title":"Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial","volume":"8","author":"Vanassche","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2023042617372754800_suad034-B15","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/ehjcvp\/pvac023","article-title":"Long-term treatment with the combination of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: outcomes during the open label extension of the COMPASS trial","volume":"8","author":"Eikelboom","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2023042617372754800_suad034-B16","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/eurheartj\/ehx658","article-title":"External applicability of the COMPASS trial: an analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry","volume":"39","author":"Darmon","year":"2018","journal-title":"Eur Heart J"},{"key":"2023042617372754800_suad034-B17","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/ehjqcco\/qcaa054","article-title":"COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: insights from the START registry","volume":"7","author":"De Luca","year":"2021","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2023042617372754800_suad034-B18","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1016\/j.jacc.2019.04.046","article-title":"Association of multiple enrichment criteria with ischemic and bleeding risks among COMPASS-eligible patients","volume":"73","author":"Darmon","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2023042617372754800_suad034-B19","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/ehjcvp\/pvac028","article-title":"Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: the XATOA registry","volume":"8","author":"Fox","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2023042617372754800_suad034-B20","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nrcardio.2017.148","article-title":"Antithrombotic therapy: COMPASS points to low-dose rivaroxaban and aspirin for secondary prevention","volume":"14","author":"Lim","year":"2017","journal-title":"Nat Rev Cardiol"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/25\/Supplement_C\/C20\/50100639\/suad034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/25\/Supplement_C\/C20\/50100639\/suad034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T17:38:34Z","timestamp":1682530714000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/25\/Supplement_C\/C20\/7143319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":20,"journal-issue":{"issue":"Supplement_C","published-online":{"date-parts":[[2023,4,26]]},"published-print":{"date-parts":[[2023,4,26]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suad034","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"type":"print","value":"1520-765X"},{"type":"electronic","value":"1554-2815"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2023,4,26]]}}}